Contributors |
|
xxi | (4) |
Abbreviations |
|
xxv | |
|
1. Chemically engineered antibodies |
|
|
1 | (26) |
|
|
|
|
|
|
|
|
|
|
1 | (1) |
|
2. Some essential features of IgG molecules |
|
|
2 | (1) |
|
|
2 | (1) |
|
|
3 | (1) |
|
3. Some further reactions of SH groups and SS bonds |
|
|
3 | (5) |
|
Properties of pyridyl disulfides |
|
|
3 | (3) |
|
SS-interchange on reduced Ig modules |
|
|
6 | (1) |
|
Alkylation of SH groups for blocking or cross-linking |
|
|
7 | (1) |
|
|
8 | (4) |
|
|
8 | (2) |
|
|
10 | (2) |
|
|
12 | (6) |
|
Precautions when handling human material |
|
|
12 | (1) |
|
|
12 | (2) |
|
|
14 | (2) |
|
Preparation of Fc-SS-pyridine and Fc-maleimide |
|
|
16 | (2) |
|
|
18 | (3) |
|
IgG antibodies from ascites or culture fluid |
|
|
18 | (1) |
|
Preparation of F(ab'y)(2) |
|
|
18 | (2) |
|
Fab'-SS-pyridine and Fab'(-SH)(1) |
|
|
20 | (1) |
|
7. Some derivatives of Fcy and Fab'y modules |
|
|
21 | (3) |
|
|
21 | (1) |
|
Thioether-linked F(ab')(2) with potential hinge SH groups |
|
|
22 | (1) |
|
Bispecific chimeric derivatives from thioether-linked F(ab')(2) |
|
|
23 | (1) |
|
|
24 | (3) |
|
2. Genetically engineered antibodies |
|
|
27 | (28) |
|
|
|
|
|
|
27 | (1) |
|
2. PCR cloning of immunoglobulin variable domains |
|
|
28 | (7) |
|
Synthesis of first strand cDNA |
|
|
28 | (2) |
|
|
30 | (3) |
|
|
33 | (2) |
|
3. The construction of engineered human variable domains |
|
|
35 | (6) |
|
|
35 | (3) |
|
|
38 | (3) |
|
4. Construction of Fvs and single-chain Fvs |
|
|
41 | (3) |
|
|
41 | (1) |
|
|
42 | (2) |
|
5. Expression of recombinant antibodies |
|
|
44 | (8) |
|
|
44 | (4) |
|
|
48 | (4) |
|
|
52 | (1) |
|
|
52 | (3) |
|
3. Production of human monoclonal antibodies from B lymphocytes |
|
|
55 | (28) |
|
|
|
|
|
|
|
|
|
|
55 | (1) |
|
|
56 | (2) |
|
|
56 | (1) |
|
|
57 | (1) |
|
|
57 | (1) |
|
3. Assays for detection of human monoclonal antibodies |
|
|
58 | (5) |
|
|
59 | (2) |
|
|
61 | (2) |
|
|
63 | (1) |
|
5. Isolation and proliferation of human B lymphocytes |
|
|
64 | (5) |
|
|
64 | (1) |
|
Isolation of PBMC from human blood |
|
|
65 | (1) |
|
Production and use of Epstein-Barr virus |
|
|
65 | (1) |
|
|
66 | (3) |
|
|
69 | (4) |
|
|
69 | (1) |
|
|
70 | (1) |
|
|
71 | (2) |
|
7. Strategies for production of human Mabs |
|
|
73 | (2) |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
74 | (1) |
|
|
75 | (1) |
|
|
75 | (4) |
|
|
76 | (2) |
|
|
78 | (1) |
|
|
78 | (1) |
|
9. Scale up of production |
|
|
79 | (2) |
|
|
81 | (1) |
|
|
81 | (2) |
|
4. Generation and selection of human monoclonal antibodies against melanoma-associated antigens: a model for production of anti-tumour antibodies |
|
|
83 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
83 | (1) |
|
2. Production of hybridomas from lymph node lymphocytes |
|
|
83 | (1) |
|
3. Identification of tumour-specific Mabs |
|
|
84 | (4) |
|
|
88 | (1) |
|
5. Antibodies packaged in eggs |
|
|
89 | (20) |
|
|
|
|
|
|
|
|
|
|
89 | (1) |
|
|
90 | (1) |
|
|
91 | (1) |
|
|
91 | (2) |
|
|
93 | (2) |
|
6. Purification of IgG from yolk |
|
|
95 | (6) |
|
7. Use of chicken antibodies |
|
|
101 | (5) |
|
|
106 | (3) |
|
6. Standardization of immunochemical procedures and reagents |
|
|
109 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
109 | (1) |
|
2. Quality of immunochemical reagents |
|
|
109 | (1) |
|
3. Standardization of immunochemical procedures |
|
|
110 | (5) |
|
|
110 | (1) |
|
Nature and availability of standard preparations |
|
|
111 | (1) |
|
Unitage of standard preparations |
|
|
112 | (3) |
|
4. Problems with the standardization of immunochemical procedures |
|
|
115 | (4) |
|
|
115 | (1) |
|
Use of multiple standards |
|
|
115 | (4) |
|
Problems due to the epitope specificity of antibodies |
|
|
119 | (1) |
|
|
119 | (1) |
|
|
119 | (2) |
|
7. Synthetic peptides in epitope mapping |
|
|
121 | (26) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
121 | (1) |
|
2. Multiple peptide synthesis on pins |
|
|
121 | (1) |
|
Cleaved or non-cleavable? |
|
|
122 | (1) |
|
|
122 | (1) |
|
|
122 | (5) |
|
Storage and handling of peptides |
|
|
126 | (1) |
|
4. Antibody (B cell) epitope mapping with synthetic peptides |
|
|
127 | (7) |
|
Direct binding of antibodies on pins |
|
|
127 | (3) |
|
Direct binding on biotinylated peptides |
|
|
130 | (2) |
|
Confirmation of relevance of binding |
|
|
132 | (2) |
|
Analoguing for detailed epitope analysis |
|
|
134 | (1) |
|
5. T cell epitope mapping with synthetic peptides |
|
|
134 | (11) |
|
|
135 | (3) |
|
Epitope mapping with T cell clones |
|
|
138 | (3) |
|
Mapping of T helper epitopes with peripheral blood mononuclear cells |
|
|
141 | (4) |
|
|
145 | (1) |
|
|
145 | (2) |
|
8. Enzyme-linked immunoassays |
|
|
147 | (30) |
|
|
|
|
|
|
147 | (1) |
|
|
147 | (5) |
|
|
147 | (2) |
|
|
149 | (3) |
|
3. Enzymes and substrates |
|
|
152 | (2) |
|
Alkaline phosphatase (EC 3.1.3.1) |
|
|
152 | (1) |
|
Horse-radish peroxidase (EC 1.11.1.7) |
|
|
153 | (1) |
|
XXX-Galactosidase (EC 3.2.1.23) |
|
|
154 | (1) |
|
4. Purification of conjugate |
|
|
154 | (1) |
|
|
155 | (1) |
|
6. Coating of the solid phase |
|
|
155 | (2) |
|
|
157 | (1) |
|
|
158 | (1) |
|
|
159 | (1) |
|
10. Buffers and substrates |
|
|
160 | (2) |
|
|
160 | (1) |
|
|
161 | (1) |
|
11. Enzyme labelling of proteins |
|
|
162 | (3) |
|
|
165 | (5) |
|
|
170 | (3) |
|
|
172 | (1) |
|
|
173 | (1) |
|
|
173 | (4) |
|
9. Enzyme amplification systems in ELISA |
|
|
177 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
177 | (2) |
|
2. Enzyme-amplified assay with colorimetric determination |
|
|
179 | (5) |
|
3. Application of fluorescence to enzyme amplification |
|
|
184 | (5) |
|
Water sources and buffers |
|
|
186 | (1) |
|
|
187 | (1) |
|
Alkaline phosphatase substrate |
|
|
187 | (1) |
|
Balance of cycling enzyme concentrations |
|
|
187 | (2) |
|
|
189 | (1) |
|
|
190 | (3) |
|
10. Photoluminescence immunoassays |
|
|
193 | (22) |
|
|
|
|
|
|
193 | (2) |
|
|
195 | (1) |
|
3. DELFIA as a label system for bioanalytical assays |
|
|
195 | (16) |
|
Microtitration plates as solid phase matrix |
|
|
197 | (2) |
|
Labelling of immunoreagents with lanthanide ions |
|
|
199 | (3) |
|
Dissociative fluorescence enhancement of lanthanides and their chelates |
|
|
202 | (1) |
|
Time-resolved fluorometry of lanthanides |
|
|
202 | (2) |
|
DELFIA multilabel measurement |
|
|
204 | (1) |
|
DELFIA FIA and IFMA: assay optimization |
|
|
205 | (4) |
|
Receptor binding assay with DELFIA technology |
|
|
209 | (1) |
|
DELFIA cytotoxic release assays |
|
|
209 | (2) |
|
4. Time-resolved fluorometric assays with stable fluorescent chelates |
|
|
211 | (1) |
|
|
212 | (1) |
|
|
213 | (2) |
|
11. Enzyme immunoassays for detection of cell surface molecules, single cell products, and proliferation |
|
|
215 | (24) |
|
|
|
|
|
|
|
|
|
|
215 | (1) |
|
|
216 | (6) |
|
Background to the technique |
|
|
216 | (1) |
|
|
216 | (5) |
|
Advantages and disadvantages |
|
|
221 | (1) |
|
Applications of the technique |
|
|
221 | (1) |
|
|
222 | (8) |
|
Background to the technique |
|
|
222 | (1) |
|
|
223 | (3) |
|
Protocol for reverse ELISPOT |
|
|
226 | (3) |
|
Advantages and disadvantages |
|
|
229 | (1) |
|
Applications of the technique |
|
|
230 | (1) |
|
|
230 | (6) |
|
Background to the technique |
|
|
230 | (1) |
|
Protocol for cell proliferation using BrdU |
|
|
231 | (1) |
|
Advantages and disadvantages |
|
|
231 | (5) |
|
Applications of the technique |
|
|
236 | (1) |
|
|
236 | (3) |
|
|
239 | (36) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
239 | (2) |
|
2. Preparation of chemically coupled immunotoxins |
|
|
241 | (12) |
|
|
241 | (1) |
|
|
242 | (11) |
|
3. Purification of chemically coupled immunotoxins |
|
|
253 | (2) |
|
Gel permeation chromatography |
|
|
253 | (1) |
|
|
254 | (1) |
|
4. Calculation of the composition of chemically prepared ITs |
|
|
255 | (1) |
|
5. Preparation of ITs by genetic engineering |
|
|
255 | (14) |
|
Extraction of RNA from B cell hybridoma cell line |
|
|
256 | (2) |
|
Preparation of DNA coding for variable regions |
|
|
258 | (2) |
|
Cloning of DNA and assembly of DNA encoding scFv and scFv-immunotoxin |
|
|
260 | (6) |
|
Expression and purification of fusion proteins |
|
|
266 | (3) |
|
6. Biochemical characterization of ITs |
|
|
269 | (1) |
|
|
270 | (1) |
|
|
271 | (4) |
A1 List of suppliers |
|
275 | (8) |
Index |
|
283 | |